<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808392</url>
  </required_header>
  <id_info>
    <org_study_id>M37P2</org_study_id>
    <nct_id>NCT00808392</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b</brief_title>
  <official_title>A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Investigate Immunogenicity and Safety of Haemophilus Influenzae Type b Vaccine in 2 - 4 Months Old Healthy Infants in China, According to the Recommended Regimen of 3 Intramuscular Doses Given One Month Apart</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will investigate safety and immunogenicity of a monovalent conjugated vaccine&#xD;
      against Haemophilus influenzae type b in healthy children aged 2 to 4 months in China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenic response measured by detection of anti-PRP antibodies by IgG enzyme linked immunosorbent assay (ELISA).</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of local and systemic reactions, adverse events (AEs), and serious adverse events (SAEs) after each single vaccination dose will be evaluated.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">916</enrollment>
  <condition>Haemophilus Influenzae Type b</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haemophilus influenzae type b vaccine</intervention_name>
    <description>3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Commercial Haemophilus influenzae type b vaccine</intervention_name>
    <description>3 doses one month apart of Haemophilus influenzae type b vaccine.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants of either sex, aged 2 - 4 months&#xD;
&#xD;
          -  In good health as determined by:&#xD;
&#xD;
               -  medical history&#xD;
&#xD;
               -  physical examination&#xD;
&#xD;
               -  clinical judgment of the investigator;&#xD;
&#xD;
          -  Available for all visits scheduled in the study and able to comply with all study&#xD;
             regulations&#xD;
&#xD;
          -  For whom written informed consent has been obtained from at least one parent or legal&#xD;
             guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Parent or legal guardian is unwilling or unable to give written informed consent to&#xD;
             participate in study&#xD;
&#xD;
          -  Infants who have received any other Haemophilus influenzae type b immunization dose&#xD;
             before&#xD;
&#xD;
          -  Infants who presented a previous disease potentially related to Haemophilus influenzae&#xD;
             type b&#xD;
&#xD;
          -  Infants who had household contact and/or intimate exposure in the previous 30 days to&#xD;
             an individual with ascertained Haemophilus influenzae type b disease&#xD;
&#xD;
          -  Premature (before 37th week of gestation) or birth weight less than 2500 g&#xD;
&#xD;
          -  History of anaphylactic shock, asthma, urticaria or other allergic reaction after&#xD;
             previous vaccinations or hypersensitivity to any vaccine component&#xD;
&#xD;
          -  Fever ≥ 38.0 °C (axillary body temperature) or/and significant acute or chronic&#xD;
             infection requiring systemic antibiotic or antiviral therapy within the past 7 days&#xD;
             before enrollment&#xD;
&#xD;
          -  Subjects with any serious chronic disease such as cardiac, neurological, metabolic,&#xD;
             hematologic, or neoplastic disease&#xD;
&#xD;
          -  Known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder&#xD;
&#xD;
          -  Subjects with any neurological disorder, e.g., epilepsy or history of seizure disorder&#xD;
&#xD;
          -  Subjects with a clinically significant genetic anomaly&#xD;
&#xD;
          -  Treatment with corticosteroids or other immunosuppressive drugs&#xD;
&#xD;
          -  Any previous treatment with parenteral immunoglobulin preparation, blood products,&#xD;
             and/or plasma derivatives&#xD;
&#xD;
          -  Any vaccination administered within one week (7 days) before enrollment and/ or any&#xD;
             planned administration of any vaccine outside the Chinese routine vaccination program.&#xD;
&#xD;
          -  Participation in any other investigational trial simultaneously&#xD;
&#xD;
          -  Planned surgery during the study period&#xD;
&#xD;
          -  Any condition, which, in the opinion of the investigator, might interfere with the&#xD;
             evaluation of the study objective&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>4 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>the CDC of Dingxing county(site no 02)</name>
      <address>
        <city>Dingxing</city>
        <state>Hebei</state>
        <zip>072650</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The CDC of Zhengding county(site no 01)</name>
      <address>
        <city>Zhengding</city>
        <state>Hebei</state>
        <zip>050800</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>December 12, 2008</study_first_submitted>
  <study_first_submitted_qc>December 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2008</study_first_posted>
  <last_update_submitted>December 26, 2011</last_update_submitted>
  <last_update_submitted_qc>December 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>prevention</keyword>
  <keyword>haemophilus influenzae type b</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Haemophilus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

